Kathryn Grandinetti
4PUBLICATIONS
26CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (4)
Sort by Publication Date:
|Feb 07, 2026
Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies.Tadashi Manabe, Hannah C Bergo, Qingtian Li
|Nov 24, 2025
Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination Strategies.Tadashi Manabe, Hannah C Bergo, Qingtian Li
|Jun 03, 2025
Discovery of KIN-8741, a Highly Selective Type IIb c-Met Kinase Inhibitor with Broad Mutation Coverage and Quality Drug-Like Properties for the Treatment of Cancer.Xiaohu S Ouyang, Kathryn B Grandinetti, Morgan Boren
|Mar 04, 2024
The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations.Eranga R Balasooriya, Qibiao Wu, Haley Ellis
Pageof 1
Frequent Collaborators
2 joint publications
Nicole Zhang
2 joint publications
Shumei Kato
2 joint publications
Wei Wu
2 joint publications
Catherine Lee
2 joint publications
Trever G Bivona
2 joint publications
Joel W Neal
2 joint publications
Paul Severson
2 joint publications
Tadashi Manabe
1 joint publications
Qibiao Wu
1 joint publications
Bryanna L Norden
